Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

Blood

Volumn 124, Issue 4, 2014, Pages 536-545

  Zhu, Yuan Xiao ^a   Braggio, Esteban ^a   Shi, Chang Xin ^a   Kortuem, K Martin ^a   Bruins, Laura A ^a   Schmidt, Jessica E ^a   Chang, Xiu Bao ^b   Langlais, Paul ^b   Luo, Moulun ^c   Jedlowski, Patrick ^a   LaPlant, Betsy ^d   Laumann, Kristina ^d   Fonseca, Rafael ^a   Bergsagel, P Leif ^a   Mikhael, Joseph ^a   Lacy, Martha ^e   Champion, Mia D ^a   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d Division of Biomedical Statistics and Informatics   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CEREBLON BINDING PROTEIN; DEXAMETHASONE; FLOTILLIN 1; IKAROS TRANSCRIPTION FACTOR; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; POMALIDOMIDE; PROTEIN CUL 4A; PROTEIN DDB 1; PROTEIN KPNA 2; PROTEIN LTF; PROTEIN PKLF; PROTEIN PRKAR 2A; PROTEIN RANGAP 1; PROTEIN SHMT 2; TRANSCRIPTION FACTOR AIOLOS; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; TREATMENT RESPONSE; UPREGULATION;

ALPHA KARYOPHERINS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CARRIER PROTEINS; CLINICAL TRIALS, PHASE II AS TOPIC; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IKAROS TRANSCRIPTION FACTOR; IMMUNOLOGIC FACTORS; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; PROGNOSIS; PROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; THALIDOMIDE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84904860974     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-557819     Document Type: Article

References (40)

1. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(1):57-65.
2. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1999;5(5):582-585. (Pubitemid 29220220)
3. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082-4085. (Pubitemid 24139577)
4. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345-1350.
5. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18): 7347-7356.
6. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454(7201):226-231. (Pubitemid 351969894)
7. Kumar SK, Lacy MQ, Hayman SR, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011;86(8):640-645.
8. Lopez-Girona A, Heintel D, Zhang LH, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol. 2011;154(3):325-336.
9. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118(18):4771-4779.
10. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11): 2326-2335.
11. Broyl A, Kuiper R, van Duin M, et al; Dutch-Belgian HOVON group; German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4): 624-627.
12. Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013:n/a-n/a.
13. Egan J, Kortuem KM, Shi C-X, et al. The myeloma genome in drug refractory extra-medullary disease identifies mutations in proteasome, cereblon and glucocorticoid pathways. ASH Annual Meeting Abstracts. 2012;120(21):3968.
14. Lohr JG, Stojanov P, Carter SL, et al; Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
15. Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38(1):23-28.
16. Neri P, Belch AR, Johnson J, et al. A miRNA risk score for the prediction of response to lenalidomide in multiple myeloma (MM) patients. ASH Annual Meeting Abstracts. 2011;118(21): 987.
17. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343(6168):301-305.
18. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
19. Tiedemann RE, Zhu YX, Schmidt J, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115(8):1594-1604.
20. Hou Y, Cui L, Riordan JR, Chang X. Allosteric interactions between the two non-equivalent nucleotide binding domains of multidrug resistance protein MRP1. J Biol Chem. 2000; 275(27):20280-20287. (Pubitemid 30457601)
21. Chang XB, Hou YX, Riordan JR. ATPase activity of purified multidrug resistance-associated protein. J Biol Chem. 1997;272(49):30962-30968. (Pubitemid 27527540)
22. published erratum appears in J Biol Chem 1998 Mar 27;273(13):7782
23. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010;11(5): R53.
24. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
25. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11): 1934-1939.
26. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
27. Broad-Novartis Encyclopedia. Available at: http://www.broadinstitute.org/ ccle/home.
28. The Genotype Tissue Expression Portal. Available at: http://www. gtexportal.org/home/.
29. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177-3188. (Pubitemid 46572502)
30. Kim J, Sif S, Jones B, et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity. 1999;10(3): 345-355. (Pubitemid 29165289)
31. Morgan B, Sun L, Avitahl N, et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. 1997;16(8):2004-2013. (Pubitemid 27170961)
32. Molnár A, Wu P, Largespada DA, et al. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. J Immunol. 1996;156(2):585-592. (Pubitemid 26028917)
33. Caballero R, Setien F, Lopez-Serra L, et al. Combinatorial effects of splice variants modulate function of Aiolos. J Cell Sci. 2007;120(Pt 15): 2619-2630. (Pubitemid 47323870)
34. Liippo J, Nera KP, Veistinen E, et al. Both normal and leukemic B lymphocytes express multiple isoforms of the human Aiolos gene. Eur J Immunol. 2001;31(12):3469-3474. (Pubitemid 34030959)
35. Copland M. Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia. Future Oncol. 2009;5(4):455-458.
36. Dupuis A, Gaub MP, Legrain M, et al. Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia. 2013;27(2): 503-507.
37. Tokunaga K, Yamaguchi S, Iwanaga E, et al. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur J Haematol. 2013;91(3):201-208.
38. Nückel H, Frey UH, Sellmann L, Collins CH, Dührsen U, Siffert W. The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. Br J Haematol. 2009;144(2):268-270.
39. Lee KM, Lee J, Park CS. Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4. Biochem Biophys Res Commun. 2012;427(3):618-622.
40. Kovac CR, Emelyanov A, Singh M, Ashouian N, Birshtein BK. BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence. J Biol Chem. 2000;275(22): 16752-16757. (Pubitemid 30398907)